- Home
- ONEG vs INTS Comparison
ONEG vs INTS Comparison
Compare ONEG & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONEG
- INTS
- Stock Information
- Founded
- ONEG 2021
- INTS 2012
- Country
- ONEG Hong Kong
- INTS United States
- Employees
- ONEG N/A
- INTS N/A
- Industry
- ONEG Homebuilding
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- ONEG Consumer Discretionary
- INTS Health Care
- Exchange
- ONEG Nasdaq
- INTS Nasdaq
- Market Cap
- ONEG 41.4M
- INTS 33.4M
- IPO Year
- ONEG 2024
- INTS 2023
- Fundamental
- Price
- ONEG $2.36
- INTS $2.23
- Analyst Decision
- ONEG
- INTS Strong Buy
- Analyst Count
- ONEG 0
- INTS 3
- Target Price
- ONEG N/A
- INTS $8.50
- AVG Volume (30 Days)
- ONEG 18.0K
- INTS 26.6K
- Earning Date
- ONEG 01-01-0001
- INTS 03-13-2025
- Dividend Yield
- ONEG N/A
- INTS N/A
- EPS Growth
- ONEG N/A
- INTS N/A
- EPS
- ONEG 0.16
- INTS N/A
- Revenue
- ONEG $63,463,000.00
- INTS N/A
- Revenue This Year
- ONEG N/A
- INTS N/A
- Revenue Next Year
- ONEG N/A
- INTS N/A
- P/E Ratio
- ONEG $15.01
- INTS N/A
- Revenue Growth
- ONEG 16.46
- INTS N/A
- 52 Week Low
- ONEG $1.96
- INTS $1.50
- 52 Week High
- ONEG $4.05
- INTS $5.94
- Technical
- Relative Strength Index (RSI)
- ONEG N/A
- INTS 49.26
- Support Level
- ONEG N/A
- INTS $1.84
- Resistance Level
- ONEG N/A
- INTS $2.27
- Average True Range (ATR)
- ONEG 0.00
- INTS 0.28
- MACD
- ONEG 0.00
- INTS -0.01
- Stochastic Oscillator
- ONEG 0.00
- INTS 56.36
About ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. It is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project include performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.